Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy

NCT02978222 is registered in ClinicalTrials.gov with Marker Therapeutics, Inc. as lead sponsor.

NCT NCT02978222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02978222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Lead sponsor
Marker Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 20, 2017
Completion date
January 15, 2020
Enrollment
120 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, platinum sensitive ovarian cancer